Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer Metastatic: early-phase trial registry
6 of 10 indexed Pancreatic Cancer Metastatic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Pancreatic Cancer Metastatic: 10 US clinical trials tracked, 6 recruiting.
Pancreatic Cancer Metastatic is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is State University of New York - Downstate Medical Center, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer-metastatic
OPEN 6 | RECR 60% | LATE 0 | EARLY 10 | RANK #1724 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Pancreatic Cancer Metastatic lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer Metastatic is recruiting above its size-band peers.
6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Cancer Metastatic trials is spread across many organizations.
State University of New York - Downstate Medical Center accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer Metastatic trials plan to enrol fewer than 100 people.
Median target enrolment is 64 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
Pancreatic Cancer Metastatic research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Panbela Therapeutics
NCT05254171
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics
NCT06922591
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Engeneic Pty Limited
NCT07049055
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Amplia Therapeutics Limited
NCT07026279
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
HealthPartners Institute
NCT06605430
Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
State University of New York - Downstate Medical Center
NCT06030622
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06168812
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
NCT06076837
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
University of Florida
NCT01652976
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04116073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer Metastatic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer Metastatic page
10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Pancreatic Cancer Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- State University of New York - Downstate Medical Center sponsors the most Pancreatic Cancer Metastatic trials on record, review their full trial history before evaluating a specific study. See State University of New York - Downstate Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer Metastatic condition card totals 10 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.